Mode of action and human relevance assessment of male CD‐1 mouse renal adenocarcinoma associated with lifetime exposure to empagliflozin-Reference-Cited by-同舟云学术

Mode of action and human relevance assessment of male CD‐1 mouse renal adenocarcinoma associated with lifetime exposure to empagliflozin

Published:2022-04-18 Issue:10 Volume:42 Page:1570-1584
ISSN:0260-437X
Container-title:Journal of Applied Toxicology
language:en
Short-container-title:J of Applied Toxicology

Author:

Phillips Jonathan A.¹^ORCID,Taub Mitchell E.²,Bogdanffy Matthew S.¹,Yuan Jing³,Knight Brian¹^ORCID,Smith James D.¹,Ku Warren W.¹

Affiliation:

1. Nonclinical Drug Safety Boehringer Ingelheim Pharmaceuticals, Inc Ridgefield Connecticut USA

2. Drug Metabolism and Pharmacokinetics Boehringer Ingelheim Pharmaceuticals, Inc Ridgefield Connecticut USA

3. Pfizer Inc Cambridge Massachusetts USA

Publisher

Wiley

Subject

Toxicology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jat.4329

Reference65 articles.

1. Juvenile cystic kidneys (jck): A new mouse mutation which causes polycystic kidneys

3. Nonclinical Safety of the Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin

4. IPCS Framework for Analyzing the Relevance of a Cancer Mode of Action for Humans

5. Brown P.(2013 5/27/2013).Invokana (canagliflozin) Pharmacology Review (FDA) NDA# 204042.application number: 204042Orig1s000. Retrieved fromhttp://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204042Orig1s000PharmR.pdf

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Type Disparity in Sodium–Glucose Cotransporter-2 Inhibitors in Incidences of Renal Cell Carcinoma: A Propensity-Score-Matched Cohort Study;Cancers;2024-06-05

2. Decreased risk of renal cell carcinoma in patients with type 2 diabetes treated with sodium glucose cotransporter‐2 inhibitors;Cancer Science;2024-04-04